Loading company
Exagen Inc.
XGN · Nasdaq · ·
Next earnings: November 3, 2026
$8.31-2.1%Sep 29 close
- 1M
- +16.6%
- 6M
- +175.9%
- 1Y
- -24.4%
- 5Y
- -41.2%
XGN · Nasdaq · ·
Next earnings: November 3, 2026
$8.31-2.1%Sep 29 close
Exagen Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $19.9M | $17.2M | +15.92% |
| Profit | -$3.2M | -$4.4M | +28.00% |
| Profit per share | -$0.13 | -$0.21 | +38.10% |
| Free Cash Flow | $3.4M | -$3.1M | +211.34% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We continue to advance Exagen’s unique mission to bring clarity to autoimmune disease,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Exagen Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Exagen Inc. has no earnings call transcript available.